Immunic
Latest round
- Series A
Last raised
- Sep 2017
Total raised
- $35M
Investors
- 7
About Immunic
Based in Munich, Germany, and founded in 2016, Immunic AG operates as a biotechnology that provides orally administered immunology therapies for patients.P. and RTW Investments. As of 2024, the company is headed by its CEO Dr. Daniel Vitt. The company bears the ticker symbol Nasdaq: IMUX. Vidofludimus Calcium is a Immunic product, which helps solution for the treatment of autoimmune diseases. Vidofludimus Calcium is an oral treatment that aims to provide coeliac disease sufferers with a compliant way to manage their condition.
Who invested in Immunic
7 investors across 3 rounds
See all investors in Immunic
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Immunic
Who invested in Immunic?
Immunic has 7 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Immunic raised?
Immunic has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Immunic last raise money?
Immunic's most recent round on record is a Series A, in Sep 2017.
What does Immunic do?
Based in Munich, Germany, and founded in 2016, Immunic AG operates as a biotechnology that provides orally administered immunology therapies for patients.
Where is Immunic headquartered?
Immunic is headquartered in Munich, Germany.
Which VCs invest in companies like Immunic?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Immunic's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Immunic? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.